false
0001640266
0001640266
2026-04-15
2026-04-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): April 15, 2026
Voyager
Therapeutics, Inc.
(Exact name of
registrant as specified in its charter)
| Delaware |
|
001-37625 |
|
46-3003182 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
75 Hayden Avenue
Lexington,
Massachusetts |
|
02421 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s telephone number,
including area code (857) 259-5340
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant
to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
| Common
Stock, $0.001 par value |
VYGR |
Nasdaq
Global Select Market |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Chief Financial Officer
On April 15, 2026, Nathan Jorgensen, Ph.D.
notified Voyager Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer
of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective May 8, 2026
(the effective time of Dr. Jorgensen’s transition, the “Effective Time”), to pursue a new opportunity. Dr. Jorgensen’s
resignation is not a result of any disagreement with the Company.
Election of Robin
Swartz
In connection with the
transition of Dr. Jorgensen, on April 20, 2026, the board of directors of the Company appointed Robin Swartz to assume the roles
of principal financial officer and treasurer of the Company, effective as of the Effective Time.
Ms. Swartz, age
55, has served as the Company’s Chief Operating Officer and Chief Business Officer since November 2024, and previously served
as the Company’s Chief Operating Officer from February 2022 to November 2024, the Company’s Principal Financial
Officer and Principal Accounting Officer from April 2024 to July 2024, the Company’s Senior Vice President, Business Operations
from September 2021 to February 2022 and the Company’s Senior Vice President, Portfolio Management and Patient Engagement
from January 2021 to August 2021. Prior to joining the Company, Ms. Swartz served in positions of increasing responsibility
beginning in 1995 at Genzyme Corporation and Sanofi Genzyme, culminating in her service at Sanofi Genzyme as Senior Vice President, Patient
and Product Services for Rare Diseases from January 2018 to June 2020 and as Senior Vice President, Head of Global and US Business
Operations from June 2015 to December 2017. Her previous roles at Sanofi Genzyme included Chief of Staff to the Executive Vice
President, Head of Sanofi Genzyme and Senior Director, Finance. Ms. Swartz spent over ten years serving in roles of increasing responsibility
in the Finance department at Sanofi Genzyme, with a focus on finance operations, internal auditing, and financial planning and analysis.
Ms. Swartz received a B.A. in political science and government from Kenyon College.
Ms. Swartz has no
family relationship with any of the executive officers or directors of the Company or any person nominated or chosen by the Company to
become a director or executive officer of the Company. There are no transactions in which Ms. Swartz has an interest requiring disclosure
under Item 404(a) of Regulation S-K.
Election of Amy Quinlan
Also in connection with
the transition of Dr. Jorgensen, on April 20, 2026, the board of directors of the Company appointed Amy Quinlan to assume the
role of principal accounting officer of the Company, effective as of the Effective Time.
Ms. Quinlan, age
51, has served as the Company’s Vice President of Finance since January 2025. Prior to joining the Company, Ms. Quinlan
served as Vice President of Finance at Vor Biopharma Inc. from September 2020 to January 2025. Before Vor Biopharma, Ms. Quinlan
served in roles of increasing responsibility at Tetraphase Pharmaceuticals, Inc., including as Senior Director, Controller from 2008
to January 2020 and as Vice President, Controller from January 2020 to September 2020. Ms. Quinlan received a B.S.
in Financial Accounting from Bryant University.
Ms. Quinlan has no family relationship with any of the executive officers
or directors of the Company or any person nominated or chosen by the Company to become a director or executive officer of the Company.
There are no transactions in which Ms. Quinlan has an interest requiring disclosure under Item 404(a) of Regulation S-K. Ms. Quinlan is
expected to enter into the Company’s standard form of indemnification agreement, a copy of which was filed as Exhibit
10.10 to the Company’s Registration Statement on Form S-1 (File No. 333-207367) filed with the SEC on October 28, 2015. Pursuant
to the terms of such agreement, the Company may be required, among other things, to indemnify Ms. Quinlan for particular expenses, including
attorneys’ fees, judgments, fines and settlement amounts incurred by her in any action or proceeding arising out of her service
as an officer of the Company.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: April 21, 2026 |
VOYAGER THERAPEUTICS, INC. |
| |
|
| |
By: |
/s/ Alfred W. Sandrock, Jr., M.D., Ph.D. |
| |
|
Alfred W. Sandrock, Jr., M.D., Ph.D. |
| |
|
Chief Executive Officer, President, and Director
(Principal Executive Officer) |
